February 2026 | Platform Engineering in the Era of Scalable Genomics
The genomics industry is shifting from building bioinformatics pipelines to platform engineering at scale.
As AI-driven analysis becomes standard, organizations must rethink how their infrastructure handles scale, reproducibility, and cross-institution collaboration.
Saurabh Gawande
CEO, NonStop io Technologies
If you're building genomics platforms today, you’ve probably noticed how quickly the underlying infrastructure requirements are changing. Sequencing costs continue to fall, genomic datasets are growing rapidly, and cloud-based analysis has become the default architecture for many labs and precision-medicine companies.
Genomic datasets are now petabyte-scale. AI/ML models require access across multiple institutions, raising privacy and infrastructure challenges.
Federated learning, training models across sites without centralizing data, is emerging as the solution, with studies showing results comparable to centralized models while maintaining compliance.
For example, studies using UK Biobank and other genomic datasets show that decentralized training approaches can achieve results comparable to centralized machine-learning models while keeping patient data within institutional boundaries.
Modern genomics integrates genomics, transcriptomics, proteomics, imaging, and clinical data. Workflow engines such as Nextflow and Cromwell (via CWL) now orchestrate these heterogeneous data types while maintaining reproducibility and provenance tracking.
Studies have shown that bioinformatics workflows must maintain consistent results across repeated experiments and varied computing environments. [2]
nstitutions like UK Biobank now combine genomic sequences, clinical records, imaging, and population health data for hundreds of thousands of participants. Federated analysis models enable cross-biobank collaboration without transferring sensitive datasets.
Studies in genomic data infrastructure show that federated approaches allow researchers to analyze datasets across multiple repositories while preserving privacy and regulatory compliance. [3]
In the early days of genomics cloud computing, each platform implemented its own proprietary workflows and pipeline formats. Today, industry standards are emerging that allow genomic workflows to run across multiple infrastructure providers.
One important organization in this space is the Global Alliance for Genomics and Health (GA4GH).GA4GH is driving interoperability with standards, WES, TES, and TRS, enabling genomic workflows to run across cloud providers and HPC environments without proprietary lock-in. [4]
Genomic data faces strict jurisdictional rules (GDPR, HIPAA, cross-border restrictions). GA4GH’s Data Connect APIs allow querying across distributed repositories without moving the data, enabling global research while maintaining compliance.
This approach enables large-scale research collaboration while maintaining compliance with regional data protection rules. [5]
Another major change in genomics platform engineering is the move from pipeline-centric workflows to data product architectures. Traditional pipelines reprocess raw genomic data every time a new analysis is required.
Modern platforms are moving from reprocessing raw data each time to creating curated, versioned, annotated datasets, “data products” reusable for biomarker discovery, disease modeling, AI training, and population studies. This reduces compute cost and analysis time significantly. [6]
These trends aren't features you bolt on, they're architectural decisions, about how data is stored, processed, and governed. Organizations building genomics platforms today must ask an important question:
Can your current platform support?
If you’re evaluating where your genomics platform stands today – what can evolve within your current architecture versus what may require deeper redesign, mapping out the engineering gaps often clarifies the next step.
Choosing the right healthcare software development partner can make or break your project. To help teams make confident decisions, we created a Healthcare Software Vendor Evaluation Checklist used by healthcare organizations evaluating digital health platform vendors.The checklist helps you assess vendors, covering regulatory experience, compliance architecture, EHR integration, delivery, and long-term fit.
If you’re evaluating where your genomics platform stands today – what can evolve within your current architecture versus what may require deeper redesign, mapping out the engineering gaps often clarifies the next step.
Biological foundation models trained on DNA, RNA, and multi-omics data are beginning to power variant interpretation, disease risk prediction, and drug discovery, but they introduce a new infrastructure challenge: building platforms that support AI training at scale with reproducibility, governance, and compliance.Stay tuned.